GlobeNewswire by notified

Nyxoah Announces Launch of Proposed Public Offering in the United States

Share

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Launch ofProposed Public Offering in the United States

Mont-Saint-Guibert, Belgium – June25, 2021, 12:30 pm CET / 6:30 amET – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it is launching an underwritten registered public offering of 2,760,000 ordinary shares in the United States (the "Offering") at an assumed public offering price of $31.461.

In connection with the Offering, Nyxoah intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares offered in the Offering on the same terms and conditions.

The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the size or terms of the Offering, including the price per ordinary share (in USD) and number of ordinary shares sold in the Offering.

Nyxoah’s ordinary shares are currently listed on Euronext Brussels under the symbol “NYXH”. An application has been made to list the ordinary shares on the NASDAQ Global Market under the same symbol.

Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the Offering. Degroof Petercam is acting as a co-manager.

A registration statement on Form F-1 has been filed with the SEC but has not yet become effective. The ordinary shares may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction.

The Offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, can be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924; Stifel, Nicolaus & Company, Incorporated at Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022; email: prospectus@cantor.com.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the terms of the Offering. Forward-looking statements are based on Nyxoah’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ. Forward-looking statements contained in this announcement are made as of this date, and Nyxoah undertakes no duty to update such information except as required under applicable law.

IMPORTANT INFORMATION
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of the Belgian Act of 11 July 2018 on the public offering of securities and the admission of securities to be traded on a regulated market, will not be eligible to participate in the offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the "Prospectus Regulation"), and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated. A prospectus will be prepared by Nyxoah in accordance with Article 3 of the Prospectus Regulation for the purpose of having the new shares that will be represented by ordinary shares admitted to trading on Euronext Brussels. In the context of the Offering and in accordance with Belgian law and the articles of association of Nyxoah, the board of directors of Nyxoah has approved a conditional capital increase with issuance of up to 4,600,000 ordinary shares within the framework of the authorized capital granted to the board of directors as set out in article 7 of the articles of association of Nyxoah.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com


1 Equivalent to a public offering price of €26.50 per ordinary share, assuming an exchange rate of  €1.00 = $1.1872, the noon buying rate in The City of New York on June 18, 2021 set forth in the H.10 statistical release of the Federal Reserve Board on June 21, 2021.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Magna Announces 2024 Annual Meeting Results10.5.2024 00:00:00 CEST | Press release

AURORA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today announced voting results from its 2024 annual meeting of shareholders held on May 9, 2024. A total of 230,328,916 Common Shares or 80.18% of our issued and outstanding Common Shares were represented in person or by proxy at the meeting. Shareholders voted in favour of each item of business, as follows: a. Election of Directors Nominee Votes FORNomineeVotes FORMary S. Chan95.27%Mary Lou Maher98.16%Hon. V. Peter Harder98.97%William A. Ruh96.46%Jan R. Hauser99.73%Dr. Indira V. Samarasekera89.07%Seetarama S. Kotagiri (CEO)99.54%Matthew Tsien96.22%Jay K. Kunkel99.83%Dr. Thomas Weber95.08%Robert F. MacLellan97.63%Lisa S. Westlake95.29% b. Other Items of Business Item Votes FORReappointment of Deloitte99.65%Say on Pay85.36% Based on the voting results, all 12 nominees were re-elected to the Board, Deloitte was reappointed as independent auditor, and the “Say on Pay” resolution was approved –

Baltic Horizon Fund Consolidated Unaudited Results for Q1 20249.5.2024 22:55:00 CEST | Press release

Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the three months of 2024. Our strategic ambitions Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from centrally located multi-functional assets aligned with our ‘Modern City Life’ strategy. These spaces are meticulously designed to ignite, elevate and enrich the lives of modern citizens and communities. The remaining results are expected to be derived primarily from government-rented premises and select suburban supermarkets and other segments. Our value propos

DBV Technologies to Participate in Upcoming Investor Conferences9.5.2024 22:30:00 CEST | Press release

Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 13, 2024 Format: Fireside Chat Time: 11:00am ET Location: Hilton Midtown Hotel, New York, NY H.C. Wainwright BioConnect Conference – May 20, 2024 Format: Fireside Chat Time: 12:00pm ET Location: NASDAQ World Headquarters, New York, NY A live webcast of each presentation will be available on the Events page on the Investors section of the Company's website www.dbv-technologies.com. A replay will also be available for 90 days after each event. About DBV Technologies DBV Technologies is

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia9.5.2024 17:06:04 CEST | Press release

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care. Strategic investments in infrastructure, technology, and talent, have led to advancements revolutionizing patient care delivery and elevating the standards of healthcare locally. These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom. Central to these achievements, King Faisal Specialist Hospital & Research Centre (KFSH&RC), renowned for its specialized care and treatments across critical fields such as oncology, cardiology, organ transplantation, and genetics has positioned itself as a leader in specialized patient care, taking the charge towards a brighter, healthier future for the Kingdom. Through its commitment to pioneering digital health initiatives, comprehensive educational programs, and

Corza Medical Named “Best Overall MedTech Company” in 8th Annual MedTech Breakthrough Awards Program9.5.2024 16:30:00 CEST | Press release

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies WESTWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corza Medical today announced that it has been selected as the winner of the “Best Overall MedTech Company” award in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market. Corza Medical provides healthcare professionals with a platform of surgical technologies and features industry-leading brands. The company partners closely with clinicians and surgical providers to create a differentiated surgical experience through remarkable products and services that save time, money, and effort. Working with diverse healthcare providers ranging from hospital administrators to private practices, this exceptional medical device

HiddenA line styled icon from Orion Icon Library.Eye